[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "In this case, we have a 3-day-old neonate with d-transposition of the great arteries (d-TGA) with intact ventricular septum and a restrictive patent foramen ovale (PFO). The key clinical findings are:\n\n1. Progressive cyanosis unresponsive to oxygen (expected in d-TGA)\n2. Prostaglandin E1 has been started but cyanosis persists (O2 sat 55%)\n3. Restrictive PFO - this is the critical issue\n4. Hemodynamically stable with adequate biventricular function\n\nIn d-TGA, the systemic and pulmonary circulations run in parallel rather than in series. Survival depends on mixing of blood between the two circulations. The main sites of mixing are:\n- Patent ductus arteriosus (kept open with PGE1)\n- Patent foramen ovale/atrial septal defect\n\nWhen the PFO is restrictive, there is inadequate mixing at the atrial level, leading to severe hypoxemia despite PGE1 therapy. The definitive treatment for d-TGA is the arterial switch operation, but this is typically performed after stabilization.\n\nThe immediate priority is to improve mixing. Balloon atrial septostomy (Rashkind procedure) is the standard emergent intervention to enlarge the atrial communication and improve mixing. This can be performed at bedside using echocardiographic guidance or in the catheterization lab.\n\nLet's consider the other options:\n- A. Emergent arterial switch: While this is the definitive surgery, it requires preparation and the infant needs stabilization first\n- C. ECMO: Not indicated when there's a correctable cause of hypoxemia and the infant is hemodynamically stable\n- D. Inhaled nitric oxide: This helps pulmonary hypertension, not the mixing problem in d-TGA\n- E. Atrial septectomy via sternotomy: This is a surgical approach that is more invasive than balloon septostomy and not the first-line intervention\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case of suspected methotrexate-induced lung toxicity.\n\nThe patient presents with:\n- 6 weeks of progressive dyspnea and dry cough\n- On methotrexate and adalimumab for rheumatoid arthritis\n- HRCT: diffuse ground-glass opacities with consolidation in peribronchovascular distribution\n- BAL: 45% lymphocytes with CD4/CD8 ratio of 0.5 (low ratio, indicating CD8 predominance)\n\nKey features of methotrexate-induced lung toxicity:\n- Methotrexate pneumonitis is a well-recognized complication\n- The most common histopathologic pattern is hypersensitivity pneumonitis (HP) pattern\n- BAL findings typically show lymphocytosis with a low CD4/CD8 ratio (CD8 predominance), which is characteristic of HP\n- The subacute presentation over weeks is consistent with HP\n\nLet me consider the options:\n\nA. Usual interstitial pneumonia (UIP) - This is more associated with idiopathic pulmonary fibrosis and has a different pattern (basal, peripheral honeycombing)\n\nB. Diffuse alveolar damage (DAD) - Can occur with methotrexate but is typically acute and more severe\n\nC. Hypersensitivity pneumonitis pattern - Most commonly associated with methotrexate lung toxicity. The BAL findings (lymphocytosis with low CD4/CD8 ratio) and imaging pattern support this\n\nD. Organizing pneumonia - Can occur but is less common than HP pattern with methotrexate\n\nE. Pulmonary alveolar proteinosis - Not typically associated with methotrexate\n\nThe clinical presentation, BAL findings (lymphocytosis with CD4/CD8 ratio <1), and imaging are all classic for hypersensitivity pneumonitis pattern, which is the most common histopathologic pattern in methotrexate-induced lung disease.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 32-year-old woman at 28 weeks gestation with severe preeclampsia\n- Developed pulmonary edema despite treatment\n- Echo: EF 65% (preserved systolic function)\n- Grade III diastolic dysfunction\n- E/e' ratio of 18 (elevated, indicating high left atrial pressure)\n- CVP of 4 mmHg (low/normal)\n\nAnalyzing each option:\n\nA. Systolic heart failure from peripartum cardiomyopathy\n- EF is 65%, which is preserved/normal\n- This rules out systolic dysfunction\n\nB. Increased pulmonary capillary permeability from endothelial dysfunction\n- Preeclampsia does cause endothelial dysfunction\n- However, the echo findings show clear cardiac abnormalities (diastolic dysfunction, elevated E/e')\n- If this were purely capillary leak, we wouldn't expect these specific cardiac findings\n\nC. Volume overload from iatrogenic fluid administration\n- CVP is only 4 mmHg, which is low/normal\n- This argues against significant volume overload\n\nD. Diastolic dysfunction from acute afterload mismatch\n- Severe preeclampsia causes acute severe hypertension (high afterload)\n- The heart has preserved EF but grade III diastolic dysfunction\n- E/e' of 18 indicates elevated left ventricular filling pressures\n- Low CVP with high left-sided filling pressures suggests the problem is left ventricular diastolic dysfunction\n- Acute afterload increase in pregnancy can cause acute diastolic dysfunction, leading to elevated LVEDP and pulmonary edema\n\nE. Mitral regurgitation from papillary muscle dysfunction\n- No mention of mitral regurgitation on echo\n- Would typically be noted if significant\n\nThe pathophysiology: In severe preeclampsia, acute severe hypertension creates an afterload mismatch. The left ventricle, which may already have some pregnancy-related changes, cannot adequately relax during diastole when facing high afterload. This leads to elevated left ventricular end-diastolic pressure, which transmits back to the pulmonary circulation causing pulmonary edema. The preserved EF with grade III diastolic dysfunction and elevated E/e' ratio perfectly fits this mechanism.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case carefully.\n\nThis patient has:\n- Ischemic cardiomyopathy with severely reduced EF (25%)\n- CRT-D in place\n- Optimal guideline-directed medical therapy (ARNI, beta-blocker, MRA, SGLT2i)\n- Scar-related reentrant VT from inferolateral LV\n- Failed catheter ablation\n- Recurrent VT storm despite amiodarone\n\nThe question asks about additional pharmacologic therapy with demonstrated mortality benefit in this specific population (patients with recurrent VT despite ablation and amiodarone).\n\nLet me consider each option:\n\nA. Mexiletine - A class IB antiarrhythmic that blocks sodium channels. When added to amiodarone, it can reduce VT episodes. The combination of amiodarone + mexiletine has been studied and shown to reduce ICD shocks in patients with recurrent VT.\n\nB. Sotalol - Class III antiarrhythmic with beta-blocking properties. Generally not preferred in severe heart failure (EF 25%) due to negative inotropic effects and proarrhythmic risk.\n\nC. Ranolazine - Late sodium current inhibitor. Some data for VT suppression but limited evidence for mortality benefit.\n\nD. Quinidine - Class IA antiarrhythmic. Associated with increased mortality in some studies and significant side effects.\n\nE. Dofetilide - Class III antiarrhythmic. Can be used in heart failure but primarily for atrial arrhythmias; significant QT prolongation risk.\n\nThe key consideration here is that mexiletine, when added to amiodarone in patients with recurrent VT, has shown benefit in reducing VT episodes and ICD shocks. The MEXICA trial and other studies have demonstrated that mexiletine added to amiodarone can reduce recurrent VT in patients who have failed other therapies.\n\nHowever, regarding mortality benefit specifically, this is challenging because none of these agents have robust mortality benefit data in this specific population. But mexiletine added to amiodarone has the best evidence for reducing VT burden in refractory cases, and reducing VT storm/ICD shocks can have survival implications.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nThe presentation describes:\n- 6-year-old boy\n- Recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis\n- Episodes occur every 4-6 weeks\n- Started at age 2\n- Episodes resolve spontaneously within 5 days\n- Completely well between episodes with normal growth\n- Elevated inflammatory markers (CRP, ESR) during episodes\n- Normal CBC\n- Negative genetic testing for FMF, TRAPS, HIDS\n\nThis is a classic presentation of PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, and Adenitis).\n\nLet me evaluate each treatment option:\n\nA. Colchicine prophylaxis - Used primarily for FMF, not first-line for PFAPA and doesn't typically induce remission\n\nB. Anakinra during episodes - IL-1 receptor antagonist, sometimes used in refractory cases but not first-line for inducing remission\n\nC. Single-dose corticosteroid at episode onset - Very effective at aborting individual episodes (often within hours), but does NOT induce remission and may actually shorten the interval between episodes\n\nD. Tonsillectomy with or without adenoidectomy - Studies show this has the highest rate of inducing complete remission in PFAPA, with success rates of 63-100% in various studies. It's considered the definitive treatment for achieving long-term remission.\n\nE. Cimetidine prophylaxis - Has been used with variable success (around 25-30% response rate) for prophylaxis but is not the most effective for inducing complete remission\n\nThe question specifically asks about \"inducing complete remission.\" While corticosteroids are excellent for treating individual episodes, tonsillectomy (with or without adenoidectomy) is the treatment most likely to induce complete and lasting remission of PFAPA syndrome.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "I need to analyze this case of severe lupus nephritis and determine the best induction regimen.\n\nCase Analysis:\n- Class IV-G (diffuse proliferative) lupus nephritis - the most severe form\n- 40% cellular crescents - indicates rapidly progressive disease\n- Wire loop lesions - classic for lupus nephritis\n- High activity index (14/24) - indicates active, potentially reversible disease\n- Low chronicity index (2/12) - suggests limited irreversible damage\n- Markedly elevated anti-dsDNA, low complement - active disease\n\nEvaluating Options:\n\nA. MMF + glucocorticoids: Standard induction therapy, shown equivalent to cyclophosphamide in many trials (ALMS trial).\n\nB. Cyclophosphamide (Euro-Lupus) + glucocorticoids: Lower-dose cyclophosphamide regimen, shown effective but designed for European (predominantly Caucasian) populations.\n\nC. Voclosporin + MMF + glucocorticoids: The AURORA trial (2021) demonstrated that adding voclosporin to MMF + low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23% at 52 weeks) compared to MMF + glucocorticoids alone. This is FDA-approved for lupus nephritis.\n\nD. Rituximab + MMF + glucocorticoids: The LUNAR trial did not show superiority of adding rituximab to MMF + glucocorticoids.\n\nE. Belimumab + cyclophosphamide + glucocorticoids: The BLISS-LN trial showed belimumab added to standard therapy (either MMF or cyclophosphamide) improved outcomes, but the combination with cyclophosphamide specifically hasn't shown superior results to the voclosporin regimen.\n\nKey Consideration:\nFor severe Class IV lupus nephritis with high activity, the question asks about \"superior renal response rates.\" The AURORA trial with voclosporin showed the most impressive improvement in complete renal response rates compared to standard of care. Voclosporin is a calcineurin inhibitor that provides rapid antiproteinuric effect combined with the immunosuppressive effects of MMF.\n\nGiven the severity of this case (crescents, high activity), the voclosporin-based regimen has demonstrated superior renal response rates in clinical trials.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nClinical Picture:\n- 72-year-old with septic shock from pneumonia\n- Norepinephrine at 0.5 mcg/kg/min (already a significant dose)\n- MAP 58 mmHg (below target of 65 mmHg)\n- Echo findings: Hyperdynamic LV (EF 75%), small LV cavity, IVC 0.8 cm with >50% respiratory variation\n- Lactate 6.2 mmol/L (significantly elevated)\n\nKey Interpretation:\nThe echo findings suggest the patient may still be hypovolemic despite \"adequate\" fluid resuscitation:\n- Small LV cavity\n- IVC <2.1 cm with >50% respiratory variation indicates fluid responsiveness\n- Hyperdynamic state\n\nHowever, the question states \"adequate fluid resuscitation\" has been given, and we need to choose a vasopressor strategy.\n\nAnalyzing Options:\n\nA. Add vasopressin 0.03 units/min - Per Surviving Sepsis Campaign guidelines, vasopressin (up to 0.03 units/min) is recommended as a second-line agent when norepinephrine is insufficient to achieve target MAP. This is a catecholamine-sparing strategy.\n\nB. Add epinephrine - Typically added when cardiac output is inadequate. This patient has a hyperdynamic heart (EF 75%), so cardiac output isn't the primary issue.\n\nC. Add phenylephrine - Pure alpha-agonist, can cause reflex bradycardia and decrease cardiac output. Generally not preferred in septic shock.\n\nD. Add angiotensin II - Reserved for refractory vasodilatory shock, typically when other agents have failed. It's a third-line option.\n\nE. Increase norepinephrine to maximum - 0.5 mcg/kg/min is already a high dose. Guidelines recommend adding a second agent rather than pushing norepinephrine to very high doses due to diminishing returns and increased adverse effects.\n\nBest Answer:\nAccording to Surviving Sepsis Campaign guidelines, vasopressin should be added as a second vasopressor when norepinephrine alone is insufficient. At 0.5 mcg/kg/min of norepinephrine with inadequate MAP, adding vasopressin is the standard approach.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this complex case systematically.\n\nKey findings:\n- 34 weeks pregnant with severe headache and focal neurological deficit\n- Severe hypertension (178/112 mmHg)\n- CT: Intracerebral hemorrhage (ICH)\n- MRV: Cerebral venous thrombosis (CVT) - superior sagittal sinus and left transverse sinus\n- Thrombocytopenia (82,000/μL)\n- Elevated LDH\n- Schistocytes on peripheral smear\n\nDiagnosis considerations:\nThe combination of thrombocytopenia, elevated LDH, schistocytes, and hypertension in pregnancy suggests:\n1. HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets)\n2. Preeclampsia with severe features\n3. Possibly TTP (but less likely given the pregnancy context)\n\nThe CVT with hemorrhagic transformation is the immediate life-threatening issue.\n\nManagement considerations:\n\nFor CVT, even with hemorrhagic transformation, anticoagulation is the standard treatment as it prevents thrombus propagation and improves outcomes. Studies (including ISCVT) have shown anticoagulation is beneficial even with ICH in CVT.\n\nHowever, this patient has features of HELLP/preeclampsia:\n- The definitive treatment for HELLP is delivery\n- At 34 weeks, the fetus is viable\n- Continuing pregnancy worsens HELLP\n\nAnalyzing options:\n\nA. Emergent cesarean + anticoagulation - Addresses both HELLP (delivery) and CVT (anticoagulation)\n\nB. Therapeutic anticoagulation alone - Addresses CVT but not the underlying HELLP\n\nC. Platelet transfusion + craniectomy - Surgical intervention is not first-line for CVT-related hemorrhage\n\nD. Plasma exchange + anticoagulation - Would be for TTP, but this presentation is more consistent with HELLP\n\nE. Magnesium + antihypertensives with delayed anticoagulation - Delays critical CVT treatment\n\nBest answer:\nGiven HELLP syndrome with CVT, the patient needs:\n1. Delivery to treat HELLP (emergent cesarean at 34 weeks)\n2. Anticoagulation for CVT\n\nOption A addresses both critical issues - delivery for HELLP and anticoagulation for CVT.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nThis 14-year-old girl has juvenile-onset SLE with:\n- Classic symptoms: fatigue, arthralgia, facial rash\n- Positive ANA (1:1280, homogeneous pattern)\n- Positive anti-dsDNA and anti-Smith antibodies (both highly specific for SLE)\n- Low complement levels (C3 and C4 both decreased)\n- Positive anti-C1q antibodies\n- Active urinary sediment (proteinuria and hematuria) suggesting renal involvement\n\nThe question specifically asks about the predictive value of anti-C1q antibodies.\n\nAnti-C1q antibodies are autoantibodies directed against the collagen-like region of C1q, the first component of the classical complement pathway. These antibodies have been extensively studied in SLE patients.\n\nKey points about anti-C1q antibodies:\n- They are found in 30-50% of SLE patients\n- They are strongly associated with lupus nephritis, particularly proliferative forms (Class III and IV)\n- They correlate with disease activity in lupus nephritis\n- The combination of anti-C1q antibodies with anti-dsDNA antibodies and low complement has high specificity for active renal disease\n- Anti-C1q antibodies have been shown to have high negative predictive value for lupus nephritis (absence makes nephritis unlikely)\n\nLooking at the options:\nA. Neuropsychiatric lupus - associated more with anti-ribosomal P, anti-NMDA receptor antibodies\nB. Proliferative lupus nephritis - strongly associated with anti-C1q antibodies\nC. Antiphospholipid syndrome - associated with antiphospholipid antibodies\nD. Lupus pneumonitis - no specific association with anti-C1q\nE. Autoimmune hemolytic anemia - associated with anti-RBC antibodies, direct Coombs test\n\nThe patient already shows evidence of renal involvement (proteinuria, hematuria), and anti-C1q antibodies are most specifically predictive of proliferative lupus nephritis.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "I need to analyze which mechanical circulatory support device provides the greatest left ventricular unloading.\n\nLet me consider each option:\n\nA. Intra-aortic balloon pump (IABP)\n- Provides modest hemodynamic support (~0.5 L/min increase in cardiac output)\n- Reduces afterload through diastolic augmentation\n- Minimal direct LV unloading\n- Least powerful MCS device\n\nB. Impella CP\n- Axial flow pump placed across aortic valve\n- Provides up to 3.5-4 L/min flow\n- Directly unloads LV by aspirating blood from LV and ejecting into ascending aorta\n- Good LV unloading\n\nC. TandemHeart\n- Percutaneous left atrial-to-femoral artery bypass\n- Provides up to 4-5 L/min flow\n- Unloads LA (indirectly unloads LV)\n- Requires transseptal puncture\n\nD. Veno-arterial ECMO (VA-ECMO)\n- Provides excellent systemic perfusion (up to 6-7 L/min)\n- However, it INCREASES LV afterload due to retrograde aortic flow\n- Does NOT unload the LV - actually increases LV wall stress\n- Often requires additional LV venting (like adding Impella) for unloading\n\nE. Impella 5.5\n- Larger axial flow pump\n- Provides up to 5.5 L/min flow\n- Directly aspirates from LV and ejects into ascending aorta\n- Provides the GREATEST direct LV unloading among these options\n- Surgically placed (requires axillary artery cutdown)\n\nThe key distinction is between devices that directly unload the LV versus those that provide circulatory support:\n\n- VA-ECMO provides the most circulatory support but actually INCREASES LV afterload\n- Impella devices directly unload the LV by removing blood from the ventricle\n- Impella 5.5 provides more flow (5.5 L/min) than Impella CP (3.5-4 L/min), thus greater LV unloading\n\nThe question specifically asks about \"greatest degree of left ventricular unloading\" - not just hemodynamic support. The Impella 5.5 provides the most direct and greatest LV unloading among the options listed.\n\nThe answer is (E)"}]